However, effectiveness of immunotherapeutics is limited due to evasion of tumor cells from immunosurveillance mechanisms (e.g., up-regulation of TIM-3 immune suppressive molecules on cancer cells after PD-1 blocking therapy) eventually leading to tumor resistance similar to chemotherapy [18, 19]. Here, HAVCR2 is linked to cancer.